trial · primary record
Petosemtamab + Pembrolizumab
Lung Cancer - Non Small Cell Squamous
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | Not stated |
| Primary completion | 2031-02-27 |
| Primary endpoint | Objective response rate per investigator assessment |
| Registry ID | NCT07353957 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:03.780Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07353957
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.